India’s PreVenTB trial has reported promising results for two candidate vaccines, VPM1002 and Immuvac. The study involved more than 12,700 household contacts of TB patients aged six years and above, reflecting real‑world conditions.
Key Developments
- VPM1002 showed 50.4% efficacy against extrapulmonary TB, a statistically significant reduction.
- In children aged 6‑14 years, VPM1002 achieved 64.6% efficacy against all forms of TB (both PTB and EPTB).
- Immuvac demonstrated over 60% efficacy against EPTB in children aged 6‑10 years and reduced progression to disease among those who acquired latent infection.
- Overall, VPM1002 provided 21.4% efficacy against all TB cases.
Important Facts
The burden of Tuberculosis remains the highest among infectious diseases, killing more people annually than COVID‑19 at its peak. In many low‑ and middle‑income countries (LMICs), incidence is 200‑300 per 100,000; elimination requires reducing this to 10‑20 per 100,000.
India, bearing one of the world’s largest TB burdens, lacks a structured vaccination strategy beyond infancy. The trial’s focus on school‑age children and adolescents highlights a potential “booster‑dose” opportunity.
Nutrition emerged as a modifier: participants with low BMI showed reduced vaccine efficacy, underscoring the need for nutritional support.
UPSC Relevance
Understanding TB control aligns with GS3 topics on health, disease burden, and public‑health policy. The role of ICMR illustrates how research institutions shape national programmes. The trial also reflects the policy‑making approach seen in earlier initiatives such as TrueNat and the emergency approval of Covaxin.
Way Forward
- Integrate VPM1002 and Immuvac into the National TB Elimination Programme as a booster for school‑age children and high‑risk household contacts.
- Scale up rapid diagnostics, including tools for sub‑clinical TB, to identify candidates for preventive therapy.
- Couple vaccination with nutritional supplementation, especially for under‑nourished populations.
- Maintain sustained public‑health financing to support early detection, preventive treatment, and vaccine logistics.
By adopting a layered strategy—early detection, preventive therapy, targeted vaccination, and nutrition—India can move closer to the TB elimination target without waiting for a “perfect” vaccine.